Zentalis Pharmaceuticals, Inc. (ZNTL)
NASDAQ (NMS) NASDAQ (NMS) Primary Summary
Zentalis Pharmaceuticals, Inc. $ZNTL Shares Sold by Almitas Capital LLC
Almitas Capital LLC trimmed its position in Zentalis Pharmaceuticals, Inc. (NASDAQ: ZNTL) by 71.4% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 457,322 shares of the company's stock after selling 1,141,944 shares during the quarter. Almitas Capital
Zentalis Pharmaceuticals: Late Stage, Lots Of Cash, Crushed By The Market
Zentalis has taken a serious beating in 2025 to date, as the market continues to value their pipeline as a liability rather than an asset. The company is in a bit of a holding pattern for now, but possible approval-worthy data are guided for the end of 2026. The market's disinterest in ZNTL creates a substantial, though risky, potential for upside as data gain more anticipation.
Zentalis Pharmaceuticals, Inc. (ZNTL) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 7:00 AM EDT Company Participants Julie Eastland - CEO, President & Director Ingmar Bruns - Chief Medical Officer Conference Call Participants Michael Ulz - Morgan Stanley, Research Division Presentation Michael Ulz Equity Analyst All right. Good morning, everyone, and thanks for joining us at the Morgan Stanley Global Healthcare Conference.
Zentalis Pharmaceuticals, Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Point72 Asset Management LP Point72 Asset Management LP | 94,854 | $128,053.37 | $439,174.02 | $311,120.65 | 242.96% |
 Arthur Mallet Regency Capital Management Inc.\DE | 29,500 | $519,102 | $137,765 | -$381,337 | -73.46% |
| RF Rekah Franca Catalyst Funds Management Pty Ltd. | 16,700 | $39,078 | $77,571.5 | $38,493.5 | 98.5% |
 Lindsey Seagraves Carson Advisory Inc. | 23,270 | $119,090.2 | $110,881.55 | -$8,208.65 | -6.89% |
| DP Drew Phillips Fortitude Family Office LLC | 209 | $489 | $977.07 | $488.07 | 99.81% |
Zentalis Pharmaceuticals, Inc. (ZNTL) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Zentalis Pharmaceuticals, Inc. ever had a stock split?
Zentalis Pharmaceuticals, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Julia Marie Eastland CEO | NASDAQ (NMS) Exchange | 98943L107 CUSIP |
| US Country | 106 Employees | - Last Dividend | - Last Split | 3 Apr 2020 IPO Date |
Overview
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical entity committed to the discovery and development of innovative small molecule treatments aimed at various cancers. Established in 2014 and headquartered in New York, New York, the company dedicates its efforts to advancing oncology treatments through scientific excellence and strategic partnerships. Zentalis has fostered licensing agreements and collaborations with industry leaders such as Pfizer, Inc., Eli Lilly and Company, GlaxoSmithKline, along with other notable organizations like Recurium IP Holdings, LLC; Mayo Foundation for Medical Education and Research; SciClone Pharmaceuticals International (Cayman) Development Ltd.; and Zentera Therapeutics (Cayman), Ltd. These alliances underscore Zentalis' commitment to leveraging collective expertise and resources to push the boundaries of cancer treatment.
Products and Services
- ZN-c3
ZN-c3 stands as Zentalis' premier product candidate, underpinned by its role as a WEE1 inhibitor, a crucial protein tyrosine kinase in cancer cell proliferation. Currently, ZN-c3 is undergoing a Phase 2 clinical trial aimed at treating advanced solid tumors, showcasing its versatility with a dual approach; it is also in a Phase 1/2 trial as a singular therapy and part of a Phase 1b trial combined with chemotherapy, specifically targeting patients with platinum-resistant ovarian cancer. Additionally, a Phase 2 monotherapy trial is evaluating ZN-c3 as a tumor agnostic option, dependent on predictive biomarker identification.
- ZN-c5
As an oral selective estrogen receptor degrader, ZN-c5 presents a promising treatment for advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. It is currently in a Phase 1/2 clinical trial, aiming to offer a new therapeutic avenue for patients battling this form of cancer.
- ZN-d5
ZN-d5 encompasses a selective inhibitor of B-cell lymphoma 2, venturing into the realm of hematologic malignancies. It finds its clinical value in a Phase 1 trial focused on non-Hodgkin's lymphoma and acute myelogenous leukemia, potentially broadening the spectrum of available treatments for these conditions.
- ZN-e4
Targeting a different aspect of oncology, ZN-e4 is an irreversible inhibitor of mutant epidermal growth factor receptor. Its involvement in a Phase 1/2 clinical trial aims to treat advanced non-small cell lung cancer, offering hope for a novel therapeutic strategy against this challenging diagnosis.
- BCL-xL heterobifunctional degraders
Zentalis is innovating beyond its primary candidates by developing BCL-xL heterobifunctional degraders. These are based on E3 ligases not expressed in platelets, sidestepping the common adverse effect of dose-limiting thrombocytopenia associated with BCL-xL inhibitors. This initiative represents the company's forward-thinking approach to overcoming treatment barriers in cancer therapy.
